Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTH6V3D)

• DTT Name: Cyclin-dependent kinase 1 (CDK1) DTT Info
• UniProt ID: CDK1_HUMAN
• Gene Name: CDK1

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[1]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[2]
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[2]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[5]

13 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-(thiazol-5-yl)-pyrimidine derivative 2	DMMQFCN	N. A.	N. A.	Patented	[6]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[7]
Indole-based analog 13	DMV7DFM	N. A.	N. A.	Patented	[6]
Isoquinoline 1,3-dione derivative 1	DMIYUAN	N. A.	N. A.	Patented	[6]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[8]
Naphthyridine and isoquinoline derivative 1	DMTGIP7	N. A.	N. A.	Patented	[6]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[9]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	DMOK7CW	N. A.	N. A.	Patented	[6]
Pyrrolo[2,3-d]pyrimidine derivative 10	DMRWG2E	N. A.	N. A.	Patented	[6]
Pyrrolo[2,3-d]pyrimidine derivative 9	DM0HU5O	N. A.	N. A.	Patented	[6]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[6]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[6]

6 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SCH 727965	DMCJLD1	Acute lymphoblastic leukaemia	2A85	Discontinued in Phase 3	[2]
BAY 10-00394	DMV2DIW	Small-cell lung cancer	2C25.Y	Discontinued in Phase 2	[10]
R547	DMK25FU	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[2]
ZK 304709	DMJ9R4A	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[2]
CGP-60474	DM4TGY0	Solid tumour/cancer	2A00-2F9Z	Terminated	[13]
Olomoucine	DMNAFG1	N. A.	N. A.	Terminated	[14]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-751250	DMOERXK	Obesity	5B81	Preclinical	[11]
ON-01135	DMEXLU5	Solid tumour/cancer	2A00-2F9Z	Preclinical	[12]

37 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(2,6-Diamino-pyridin-3-yl)-phenyl-methanone	DMWRCM1	Discovery agent	N.A.	Investigative	[15]
10Z-Hymenialdisine	DMIRSA5	Discovery agent	N.A.	Investigative	[16]
2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	DM27YTF	Discovery agent	N.A.	Investigative	[17]
3,4-bis(indol-3-yl)maleimide derivative	DMEQ1HC	Discovery agent	N.A.	Investigative	[18]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[19]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[19]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[19]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[19]
4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	DM4YFU5	Discovery agent	N.A.	Investigative	[20]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	DMDW3SX	Discovery agent	N.A.	Investigative	[20]
4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	DMONKDQ	Discovery agent	N.A.	Investigative	[17]
9-Nitropaullone	DM8LUYM	Discovery agent	N.A.	Investigative	[11]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[21]
alsterpaullone 2-cyanoethyl	DMDI2KH	Discovery agent	N.A.	Investigative	[22]
aminopurvalanol A	DMKLC3O	N. A.	N. A.	Investigative	[22]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[23]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[18]
BMS-265246	DM6LPIG	Discovery agent	N.A.	Investigative	[24]
Cdk1 inhibitor	DMNW12R	Discovery agent	N.A.	Investigative	[22]
Cdk1/2 inhibitor III	DMS62T0	Discovery agent	N.A.	Investigative	[25]
CGP74514A	DMU5984	Discovery agent	N.A.	Investigative	[26]
CVT-313	DMSEK5W	Discovery agent	N.A.	Investigative	[22]
IN1535	DMKFE6X	Discovery agent	N.A.	Investigative	[27]
Indirubin-3'-monoxime	DMLRQH0	Discovery agent	N.A.	Investigative	[28]
Indirubin-5-sulfonate	DM08VHZ	Discovery agent	N.A.	Investigative	[29], [30]
JNJ-7706621	DMHTYBS	Discovery agent	N.A.	Investigative	[31]
K00024	DMP8M9Q	Discovery agent	N.A.	Investigative	[32]
Microxine	DM7Y9AD	Pain	MG30-MG3Z	Investigative	[33]
NU6140	DMCUSG3	Discovery agent	N.A.	Investigative	[34]
PF-228	DM32FKD	Discovery agent	N.A.	Investigative	[35]
PMID18986805C9b	DMFU6AI	Discovery agent	N.A.	Investigative	[36]
PMID19115845C89S	DMB9F2L	Discovery agent	N.A.	Investigative	[37]
Purvalanol A	DMNQ7TM	Discovery agent	N.A.	Investigative	[11]
Quinoxaline1	DMRWXH4	Discovery agent	N.A.	Investigative	[22]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[18]
SU9516	DMQHG0R	Discovery agent	N.A.	Investigative	[38]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[23]

References

• [1] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [2] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [5] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [6] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [7] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [8] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [9] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [10] National Cancer Institute Drug Dictionary (drug id 770319).
• [11] Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76.
• [12] Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3): 323-338.
• [13] Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem. 2005 Mar 24;48(6):1886-900.
• [14] Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71.
• [15] 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4.
• [16] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [17] 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
• [18] Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
• [19] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [20] Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
• [21] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [22] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [23] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [24] A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.
• [25] 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
• [26] 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6.
• [27] M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6.
• [28] The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56.
• [29] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [30] Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex. Eur J Biochem. 2004 Jun;271(11):2280-90.
• [31] Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
• [32] Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30.
• [33] Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod. 2001 Apr;64(4):525-6.
• [34] Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
• [35] Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
• [36] Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
• [37] First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
• [38] SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31.